Deborah Gordon
Psychiatry · Cullman, ALNPI 1023091071
Payments from drug & device makers
Across 189 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$853
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$570
- Otsuka America Pharmaceutical, Inc.$381
- Alkermes, Inc.$333
- Supernus Pharmaceuticals, Inc.$297
- Vanda Pharmaceuticals Inc.$222
- plus $998 from 10 others
What the payments were for
- Food & beverage$3,57698%
- Education$782%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 35 | $853 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 26 | $570 |
| Otsuka America Pharmaceutical, Inc. | 26 | $381 |
| Alkermes, Inc. | 16 | $333 |
| Supernus Pharmaceuticals, Inc. | 18 | $297 |
| Vanda Pharmaceuticals Inc. | 12 | $222 |
| Corium, LLC | 12 | $179 |
| Lundbeck LLC | 8 | $176 |
| Teva Pharmaceuticals USA, Inc. | 10 | $164 |
| Indivior Inc. | 7 | $127 |
| E.r. Squibb & Sons, L.L.C. | 5 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $84 |
| AbbVie(2 entities) | 4 | $64 |
| Neurocrine Biosciences, Inc. | 3 | $46 |
| Sunovion Pharmaceuticals Inc. | 2 | $37 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
How this compares
$3,654 in reported general payments places this provider in the 80th percentile of 400 psychiatry providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 13 | $42,427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $853 | $42,42713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Cullman
- Ajmal KhanCullman$7K
- Matthew MacalusoBirmingham$2.8M
- Richard SheltonBirmingham$2.4M
- Michael FalolaTrussville$2.2M
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Lori DavisTuscaloosa$515K
- Scariya KumaramangalamHuntsville$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.